Vinblastine, bleomycin and cisplatin for recurrent or metastatic squamous cell carcinoma of the head and neck. 1982

D J Perry, and M D Weltz, and A W Brown, and R L Henderson, and W J Neglia, and J L Berenberg

Forty-two patients with recurrent or metastatic squamous cell carcinoma of the head and neck were treated with vinblastine, bleomycin, and cisplatin. All patients had received prior surgery, radiation or chemotherapy and all had measurable disease. Forty-five percent of the patients responded with a median duration of response of eight months and median survival of nine months. Six patients (14%) were complete responders and had a median duration of response of 12 months and median survival of 24+ months. Thirteen patients (31%) were partial responders and had a median duration of response of seven months and survival of 13 months. Toxicity was mild with nausea and vomiting occurring in all patients after cisplatin. There were two cases of bleomycin-induced pulmonary fibrosis and two cases of mild renal insufficiency (creatinine clearance level, 45 cc/min). This regimen compares favorably with other published regimens for advanced head and neck cancer.

UI MeSH Term Description Entries
D007822 Laryngeal Neoplasms Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS. Cancer of Larynx,Laryngeal Cancer,Larynx Neoplasms,Cancer of the Larynx,Larynx Cancer,Neoplasms, Laryngeal,Cancer, Laryngeal,Cancer, Larynx,Cancers, Laryngeal,Cancers, Larynx,Laryngeal Cancers,Laryngeal Neoplasm,Larynx Cancers,Larynx Neoplasm,Neoplasm, Laryngeal,Neoplasm, Larynx,Neoplasms, Larynx
D009062 Mouth Neoplasms Tumors or cancer of the MOUTH. Cancer of Mouth,Mouth Cancer,Oral Cancer,Oral Neoplasms,Cancer of the Mouth,Neoplasms, Mouth,Neoplasms, Oral,Cancer, Mouth,Cancer, Oral,Cancers, Mouth,Cancers, Oral,Mouth Cancers,Mouth Neoplasm,Neoplasm, Mouth,Neoplasm, Oral,Oral Cancers,Oral Neoplasm
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D010610 Pharyngeal Neoplasms Tumors or cancer of the PHARYNX. Cancer of Pharynx,Pharyngeal Cancer,Cancer of the Pharynx,Neoplasms, Pharyngeal,Neoplasms, Pharynx,Pharnyx Cancer,Pharynx Neoplasms,Cancer, Pharnyx,Cancer, Pharyngeal,Cancers, Pharnyx,Cancers, Pharyngeal,Neoplasm, Pharyngeal,Neoplasm, Pharynx,Pharnyx Cancers,Pharyngeal Cancers,Pharyngeal Neoplasm,Pharynx Cancer,Pharynx Cancers,Pharynx Neoplasm
D001761 Bleomycin A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. BLEO-cell,Blanoxan,Blenoxane,Bleolem,Bleomicina,Bleomycin A(2),Bleomycin A2,Bleomycin B(2),Bleomycin B2,Bleomycin Sulfate,Bleomycins,Bleomycinum Mack,Bléomycine Bellon,BLEO cell,BLEOcell,Bellon, Bléomycine,Mack, Bleomycinum,Sulfate, Bleomycin
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration

Related Publications

D J Perry, and M D Weltz, and A W Brown, and R L Henderson, and W J Neglia, and J L Berenberg
January 1994, ORL; journal for oto-rhino-laryngology and its related specialties,
D J Perry, and M D Weltz, and A W Brown, and R L Henderson, and W J Neglia, and J L Berenberg
September 1984, Cancer treatment reports,
D J Perry, and M D Weltz, and A W Brown, and R L Henderson, and W J Neglia, and J L Berenberg
October 2015, Auris, nasus, larynx,
D J Perry, and M D Weltz, and A W Brown, and R L Henderson, and W J Neglia, and J L Berenberg
December 2004, Seminars in oncology,
D J Perry, and M D Weltz, and A W Brown, and R L Henderson, and W J Neglia, and J L Berenberg
September 2018, Expert review of anticancer therapy,
D J Perry, and M D Weltz, and A W Brown, and R L Henderson, and W J Neglia, and J L Berenberg
September 1984, The Medical journal of Australia,
D J Perry, and M D Weltz, and A W Brown, and R L Henderson, and W J Neglia, and J L Berenberg
May 2015, Journal of the National Comprehensive Cancer Network : JNCCN,
D J Perry, and M D Weltz, and A W Brown, and R L Henderson, and W J Neglia, and J L Berenberg
October 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
D J Perry, and M D Weltz, and A W Brown, and R L Henderson, and W J Neglia, and J L Berenberg
October 1990, American journal of clinical oncology,
D J Perry, and M D Weltz, and A W Brown, and R L Henderson, and W J Neglia, and J L Berenberg
February 1997, Journal of chemotherapy (Florence, Italy),
Copied contents to your clipboard!